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ABSTRACT
Objective To evaluate the cost effectiveness of routine
screening for postnatal depression in primary care.
Design Cost effectiveness analysis with a decision model
of alternative methods of screening for depression,
including standardised postnatal depressionand generic
depression instruments. The performance of screening
instruments was derived from a systematic review and
bivariate meta-analysis at a range of instrument cut
points; estimates of other relevant parameters were
derived fromliterature sourcesand relevant databases. A
decision tree considered the full treatment pathway from
the possible onset of postnatal depression through
identification, treatment, and possible relapse.
Setting Primary care.
Participants A hypothetical population of women
assessed for postnatal depression either via routine care
only or supplemented by use of formal identification
methods six weeks postnatally, as recommended in
recent guidelines.
Main outcome measures Costs expressed in 2006-7
pricesandimpactonhealthoutcomesexpressedinterms
of quality adjusted life years (QALYs). The time horizon of
the analysis was one year.
Results The routine application of either postnatal or
general depression questionnaires did not seem to be
cost effective compared with routine care only. The
Edinburgh postnatal depression scale (at a cut point of
16) had an incremental cost effectiveness ratio (ICER) of
£41103 (€45398, $67130) per QALY compared with
routine care only. The ICER for all other strategies ranged
from £49928 to £272463 per QALY versus routine care
only, while the probability that no formal identification
strategy was cost effective was 88% (59%) at a cost
effectiveness threshold of £20000 (£30000) per QALY.
While sensitivity analysis indicated that the cost of
managingincorrectlyidentifieddepression(falsepositive
result) was an important driver of the model, formal
identification approaches did not seem to be cost
effective at any feasible estimate of this cost.
Conclusions Formal identification methods for postnatal
depression do not seem to represent value for money for
the NHS. The major determinant of cost effectiveness
seems to be the potential additional costs of managing
women incorrectly diagnosed as depressed. Formal
identification methods for postnatal depression do not
currently satisfy the National Screening Committee’s
criteria for the adoption of a screening strategy as part of
national health policy.
INTRODUCTION
Depressionaccountsforthegreatestburdenamongall
mental health problems and by 2020 is expected to
become the second most common general health
problem.
1 Postnatal depression is an important cate-
goryofdepression,withover11%ofwomenexperien-
cing major or minor postnatal depression six weeks
postnatally.
2 There is now considerable evidence to
showthatpostnataldepressionhasasubstantialimpact
on the mother and her partner,
3 the family,
4 mother-
baby interactions,
5 and the longer term emotional and
cognitive development of the baby,
6 especially when
depression occurs in the first year of life.
7
Though clinically and cost effective treatments are
available,
89less than half of cases of postnatal depres-
sionaredetectedinroutineclinicalpractice.
910Formal
strategies for screening and case identification (such as
standardised postnatal questionnaires, standardised
generic questionnaires for depression, and prenatal
screening for known risk factors for postnatal depres-
sion) have been advocated but are controversial.
1112
The National Screening Committee has clear criteria
that must be satisfied before the adoption of formal
screening strategies.
13 These criteria consist of 23
items relating to the condition, the test, the treatment,
and the proposed screening programme.
14 In particu-
lar, screening strategies are assessed to ensure that the
screening does more good than harm at a reasonable
cost. When these criteria were previously applied to
formal screening strategies for postnatal depression,
there was insufficient clinical and economic evidence
to support their implementation.
12 Nevertheless, these
strategiesare widelyused incurrent practice,withpar-
ticular focus on the Edinburgh postnatal depression
scale (EPDS).
8
Furthermore,recentclinicalguidelinesissuedbythe
National Institute for Health and Clinical Excellence
(NICE) recommend the use of brief case finding ques-
tions to identify possible postnatal depression (box 1),
with the use of self report measures such as the
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anxiety and depression scale (HADS), or the patient
health questionnaire (PHQ-9) as part of subsequent
assessment or for routine monitoring.
8 A specific
recommendationwas madefor the use of briefgeneric
case finding questions (the Whooley questions) that
had previously been validated in older men but not
postnatal women.
8 This guidance, however, did not
formally consider the cost effectiveness of such strate-
gies. In view of the uncertainty surrounding this issue,
the United Kingdom National Institute for Health
Research (NIHR)-Health Technology Assessment
Programme prioritised a review of the clinical and
cost effectiveness of formal identification methods for
postnatal depression in primary care. A full technical
report is published elsewhere.
15 Here we provide a
summary of the cost effectiveness analysis and policy
implications of this policy driven evidence review.
METHODS
We carried out several formal systematic reviews of
identificationmethodsandtheircorrespondingperfor-
mance and developed an economic model to evaluate
the costs and health outcomes associated with each.
This model took the form of a decision tree and con-
sidered the full treatment pathway from the possible
onset of postnatal depression through identification,
treatment, and possible relapse (figure).
The model evaluated a hypothetical population of
women managed in primary care six weeks postna-
tally. We assumed that a proportion of the women
were depressedbutthatonly somehadbeen identified
assuchthroughroutinecare.Atthistimeaformaliden-
tification method could be administered on the entire
population of postnatal women. As screening and case
finding instruments are imperfect diagnostic instru-
ments, this might identify some depressed women not
detected through routine care, but it might also incor-
rectly identify some women who were not depressed.
Women were assumed to have a diagnosis of depres-
sion if they were positively identified by either the for-
malidentificationmethod(whenapplicable)orroutine
Box 1: The Whooley questions
Clinical guidance issued by NICE in 2007 recommends that healthcare professionals ask
two questions at a woman’s first contact with primary care, again at her booking visit, and
again postnatally (usually at 4-6 weeks and 3-4 months):
 During the past month, have you often been bothered by feeling down, depressed, or
hopeless?
 During the past month, have you often been bothered by little interest or pleasure in
doing things?
A third question should be considered if the woman answers “yes” to either of the initial
questions:
 Is this something you feel you need or want help with?
Depressed
Not depressed
Depressed
Depressed
Not depressed
No relapse
Relapse
No relapse
Depressed
Does not respond
Does not respond
Relapse
Responds
Responds
Continues
Discontinues
Status at end point Relapse Responds to treatment Continues with treatment
Structured
psychological therapy
with supportive care
Yes
Yes
Yes
Yes
Yes*
No†
No
No†
No
Depressed
Depressed
Depressed
Positive
Treatment applied True status Screening result Screening model
Treatment model
Negative
Not screened
Depressed
Not depressed
Depressed
Not depressed
Depressed
Not depressed
Positive
Negative
Not screened
Identified as depressed
through routine care
Not identified as depressed
through routine care
*Identified as not depressed before treatment completed
†Patient returns to GP during follow-up and, if identified as depressed at this point, treatment started
Schematic of screening and treatment models
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sionwereofferedadditionaltreatment(box2)whileall
others received usual postnatal care. All women were
followedupforayear.Tofacilitatethemodellingofthe
postnatal period, we assumed that women who were
not depressed six weeks postnatally remained so until
the model end point.
The analysis was conducted from the perspective of
the NHS and personal social services, with costs
expressed in 2006-7 prices and health outcomes
expressed in quality adjusted life years (QALYs). We
did not apply discounting because the time horizon of
theanalysiswasonlyoneyear.Themodelwasprobabil-
istic: input parameters were entered into the model as
probabilitydistributionstoreflectuncertaintysurround-
ing the mean estimates. We used Monte Carlo simula-
tion(over10000iterations)topropagatethisuncertainty
throughoutthemodelandsensitivityanalysistoexplore
the impact of alternative model assumptions.
Data sources
To specify the range of validated case finding and
screening techniques and to establish their diagnostic
performance characteristics, we undertook a compre-
hensive search across 20 electronic databases (includ-
ing forward citation searching of key literature,
personal communication with authors, and scrutiny
of reference lists
15). We identified numerous generic
and specific screening strategies for postnatal
depression, 14 of which had been validated among
women during pregnancy or the postnatal period. By
farthemostcommonlyusedidentificationmethodwas
the Edinburgh postnatal depression scale, a specially
developed standardised postnatal questionnaire.
Other methods identified included standardised gen-
eric questionnaires such as the Beck depression inven-
tory. Both of these methods generate a score on a
particular scale—when a patient scores at or above a
particular cut point clinically significant depression is
assumed to be present.
15 The performance (sensitivity
and specificity) of each method depends critically on
the cut point chosen (table 1).
We used a bivariate meta-analysis to derive the sen-
sitivity and specificity of the alternative formal identi-
fication methods. This meta-analysis formed part of a
wider portfolio of research that assessed the accuracy,
acceptability, clinical effectiveness, and cost effective-
ness of formal identification methods for postnatal
depression.
15 The bivariate model was fitted with a
generalisedlinearmixedmodelapproachtothebivari-
ate meta-analysis of sensitivity and specificity.
17 This
approach uses the exact binomial distribution to
describe variability of sensitivity and specificity within
a study rather than the normal approximation as ori-
ginally proposed.
18
For “major or minor” depression there were suffi-
cient data to pool the Edinburgh postnatal depression
scaleatvariouscutpoints(7-16inclusive)andtheBeck
depression inventory at cut point 10. We did not con-
sidertheWhooleyquestionsinthebasecasebecauseof
lack of data available to pool estimates as part of the
bivariate meta-analysis and concerns as to the absence
of data in postnatal women. For the purposes of the
probabilistic model, we modelled the sensitivity and
specificity on the log odds scale using normal distribu-
tions. The correlation between sensitivity and specifi-
citywasreflectedintheprobabilisticanalysisusingthe
Cholesky decomposition of the covariance matrix.
19
Weusedanestimateoftheprevalenceofdepression
among postnatal women six weeks postnatally from a
previous systematic review.
2 In the absence of specific
data on postnatal depression, we derived the estimate
of the probability that depression is detected via rou-
tine care at six weeks postnatally from a UK follow-up
study of detection rates for depression and anxiety in
primary care.
20 The estimate of the probability that
postnatal depression is detected when a woman with
undiagnosed depression returns to her general practi-
tioner during the follow-up period was also derived
from thisstudy.The robustnessof our modelto uncer-
tainty around the estimate of prospective detection
rates was formally examined within our probabilistic
sensitivity analysis.
Estimates of the probabilities that women discon-
tinue treatment, do not respond to treatment, or
relapse after responding to treatment (see box 2) were
adopted from data used in the most recent evidence
synthesis undertaken within the recent NICE clinical
guideline.
8
Table 2 summarises the model’s parameters.
Box 2: Treatment for postnatal depression
The recent NICE clinical guidance presented a decision analytical model that assessed the
relativecosteffectivenessoftwo alternativepsychological treatmentsforwomen withmild
to moderate depression in the postnatal period: structured psychological therapy (as
exemplified by manualised cognitive behavioural therapy delivered by a clinical
psychologist) and non-directive counselling (for example, that based on Rogerian
principles and delivered by a primary care practice counsellor); full descriptions of these
treatments are given in the guidance.
8 We reconstructed this model with updated
parameter inputs and carried out probabilistic Monte Carlo simulation over 10000
iterations. By adopting a conventional threshold of willingness to pay of £20000-30000
per quality adjusted life year (QALY), we found that structured psychological therapy is a
cost effective treatment for mild to moderate postnatal depression, with an incremental
cost effectiveness ratio (ICER) of £17481 per QALY versus no treatment. The ICER
compares the additional costs that one strategy incurs over another with the
corresponding additional health benefits.
16 Non-directive counselling was not cost
effective, with an ICER of £66275 per QALY versus structured psychological therapy.
Women with a diagnosis of postnatal depression in our model were therefore assumed
to be offered structured psychological therapy as detailed in the NICE report. This included
eight 50 minute sessions with a clinical psychologist, three 10 minute appointments with
her general practitioner, four 45 minute home visits from a health visitor (a qualified nurse
specially trained in health assessment and promotion in the community), and a single one
hour home visit from a community psychiatric nurse. As in the NICE model, each woman
would either continue or discontinue treatment and would either respond to treatment or
not. If the woman responded then there was a possibility of relapse. If the woman did not
respond then she remained depressed.
Women with an incorrect diagnosis were assumed not to receive any of the sessions
with the clinical psychologist but did receive the supportive care. Women with
undiagnosed depression were assumed to return to their general practitioner during the
follow-up period, at which time there was a possibility of receiving a diagnosis and being
offered treatment; meanwhile there was a possibility of these women recovering under
usual postnatal care. Full details are provided in the technical report.
15
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Critical to the cost effectiveness of screening and case
finding for postnatal depression is the impact of early
identification and management on a woman’s quality
of life. To estimate QALYs, we assessed the quality of
life associated with different health states in terms of
preference weights based on published evidence.
21 In
the absence of published weights specific for postnatal
depression, we assumed that affected women experi-
ence the quality of life associated with “moderate
depression,”whilewomenwithoutdepression(includ-
ing those in remission) experience the quality of life
associated with “remission.”
Costs
The costs associated with formal identification meth-
ods are also critical to their cost effectiveness. These
include the cost of administering the method, the cost
of any subsequent treatment, and the costs associated
with incorrect diagnosis. We established estimates of
time and cost from published data or from expert opi-
nion.
Estimates for NHS unit costs were derived from
national reference costs.
22 In common with the
assumptions used with the NICE clinical guideline,
structured psychological therapy consisted of eight
50 minute sessions with a clinical psychologist
(£446.67) plus the following supportive care: three
10 minute appointments with a general practitioner
(£76.50),four45minutehomevisitsfromahealthvisi-
tor (£278.20), and a single one hour home visit from a
community psychiatric nurse (£59.30).
Estimatedadministrationcostswere£7.57(fivemin-
utes of a health visitor’s time at £91 an hour) for the
Edinburgh postnatal depression scale and £8.59 (five
minutes at £91 an hour plus the $2 licence fee) for the
Beck depression inventory.
23
Womenwithundiagnoseddepressionwereassumed
to make an additional 10 minute visit to their general
practitioner during the follow-up period (£25.50). We
assumed that women without depression who were
wrongly identified as depressed would not receive
any of the sessions with the clinical psychologist but
would receive all the supportive care (total cost
£414); this assumption was returned to in a sensitivity
analysis.
Sensitivity analyses
We identified several important drivers of the model:
the cost incurred by and approach to managing those
wrongly identified as depressed (false positives); and
thedecisiontoincludeorexcludeformalidentification
strategies not evaluated in the bivariate meta-analysis
becauseofinsufficientdata.Theimpactofthesedrivers
on the results of the model was explored through sen-
sitivity analysis with a series of alternative scenarios.
Scenario 1—The cost incurred by managing women
with a false positive diagnosis is a particularly impor-
tant driver of the model that is subject to considerable
uncertainty. The base case estimate of this cost (£414)
wascalculatedontheassumptionthatwomenwrongly
identifiedasdepressedwouldreceiveallofthesuppor-
tivecareassociatedwithstructuredpsychologicalther-
apy before being identified as not depressed. As this
estimate might well be conservative, we considered
an alternative scenario whereby this cost was assumed
to be that of a single consultationwith a general practi-
tioner (£25.50), on the optimistic assumption that
women identified as depressed by a formal identifica-
tion method would be referred to a general practi-
tioner, who would then immediately make the
correct diagnosis.
Scenario2—Wealsoconsideredtheimpactofusinga
complementary ideal identification test, such as the
structured clinical interview for DSM-IV axis I disor-
ders (SCID), for those identified as depressed by a for-
mal identification method. We assumed that this
interview took 30 minutes of a health visitor’s time to
administer (£45.50) and had a sensitivity and specifi-
city of 100%; this mitigated the cost of managing false
positives.
Scenario 3—We evaluated the impact of considering
the Whooley questions as an alternative identification
Table 1 |Performance of two methods of identification of postnatal depression in base case according to different cut points
Cut point
Sensitivity Specificity
Co-variance Log odds Variance Mean Log odds Variance Mean
Edinburgh postnatal depression scale (EPDS):
7 2.3346 1.7439 0.9117 0.7075 0.4125 0.6699 −0.1164
8 2.3379 0.9962 0.9120 1.0744 0.7713 0.7454 0.1702
9 1.7565 1.0652 0.8528 1.5274 0.8888 0.8216 0.0457
10 1.4962 0.3514 0.8170 1.8373 1.3740 0.8626 −0.0524
11 0.9548 0.5324 0.7221 2.3261 1.6619 0.9110 −0.3808
12 0.7563 0.2095 0.6805 2.5959 1.4008 0.9306 −0.2222
13 0.6716 0.6313 0.6619 2.5431 0.7443 0.9271 −0.3553
14 0.1326 0.0008 0.5331 3.1069 1.1104 0.9572 −0.0282
15 −0.4431 0.0301 0.3910 3.7755 0.2873 0.9776 0.0930
16 −0.7875 0.3989 0.3127 4.5233 0.1812 0.9893 0.2689
Beck depression inventory (BDI):
10 0.9408 0.4659 0.7193 2.2675 0.4583 0.9061 0.4621
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clinical guidance and its subsequent policy relevance.
Thiswasnotconsideredinthebasecasebecauseofthe
lack of data available to pool estimates as part of the
bivariate meta-analysis and concerns as to the absence
of validation data in a postnatal population. Given
these limited data, the Whooley questions were
assumed to have the sensitivity (0.96, 95% confidence
interval0.86to0.99)andspecificity(0.89,0.87to0.91)
reported by Arroll et al in 2005
24 and were assumed to
take a health visitor one minute to administer (£1.52).
RESULTS
We have presented our results in two ways: firstly,
mean lifetime costs and QALYs of each formal identi-
fication method with the cost effectiveness of each
method compared with incremental cost effectiveness
ratios (see box 2); and, secondly, decision uncertainty
as the probability that each formal identification
method is considered the most cost effective strategy
for a given cost effectiveness threshold.
Table 3 summarises the results of the base case ana-
lysis. No formal identification method seemed to be
cost effective under a conventional willingness to pay
threshold of £20000-30000 per QALY,
25 with the
strategy of routine care the most likely to be cost effec-
tive. Adopting the Edinburgh postnatal depression
scale with a cut point of 16 was the least costly and
effective formal identification method, with an esti-
mated incremental cost effectiveness ratio of £41103
per additional QALY compared with routine care
alone. The incremental cost effectiveness ratio for all
other screening strategies ranged from £49928 to
£272463 per QALY versus routine care only. The
costs of managing those wrongly diagnosed as
depressed represented a key driver of these results; as
such,strategiesadoptingformalidentificationmethods
with higher specificity were associated with more
favourable incremental cost effectiveness ratios.
Sensitivity analyses
Table 4 summarises the results of the sensitivity ana-
lyses. The assumption of a lower cost associated with
managing those wrongly diagnosed as depressed had
two important consequences: the incremental cost
effectivenessratiosofstrategiesadoptingidentification
methods became more favourable; and the ranking of
non-dominated strategies became less dependent on
the specificity of the identification method adopted.
When the cost of managing those wrongly diagnosed
was assumed to be £25.50, using the Edinburgh post-
natal depression scale with a cut point of 10 seemed
borderlinecosteffectivewithanincrementalcosteffec-
tiveness ratio of £29186 per additional QALY.
Table 2 |Parameters of model used to determine cost effectiveness of screening for postnatal depression in primary care
Parameter Mean (SE*) Distribution Source
Clinical parameters
Prevalence of major or minor depression 0.1130(0.0221) Normal Gaynes et al (2005)
2
Probability of identification ofdepression viaroutinecare at6 weeks postnatally 0.3864(0.0516) Beta Kessler et al (2002)
20
Probability of GP identification of depression at 32 weeks postnatally 0.4074(0.0663) Beta Kessler et al (2002)
20
Absolute risk of discontinuation (routine care) 0.0861(0.0287) Normal NICE (2007)
8 (revised)
Relative risk of discontinuation (structured psychological therapy) 2.66 (1.9783) Normal NICE (2007)
8 (revised)
Absolute risk of no improvement (routine care) 0.6037(0.0514) Normal NICE (2007)
8 (revised)
Relative risk of no response (structured psychological therapy) 0.63 (0.1276) Normal NICE (2007)
8 (revised)
Absolute risk of relapse (routine care) 0.3120(0.0752) Normal NICE (2007)
8 (revised)
Relative risk of relapse (structured psychological therapy) 0.59 (0.2525) Normal NICE (2007)
8 (revised)
Utility parameters
Moderate depression 0.63 (0.0275) Beta Revicki and Wood (1998)
21
Remission without maintenance treatment 0.86 (0.0191) Beta Revicki and Wood (1998)
21
Cost parameters
BDI licence fee (per test) $2/£1.02† Fixed Pearson
23; FT.com
Health visitor (per hour) £91.00 Fixed Curtis (2007)
22
Health visitor (travel) £1.30 Fixed Curtis (2007)
22
Clinical psychologist (per hour) £67.00 Fixed Curtis (2007)
22
General practitioner (per hour) £153.00 Fixed Curtis (2007)
22
Community psychiatric nurse (per hour) £58.00 Fixed Curtis (2007)
22
Community psychiatric nurse (travel) £1.30 Fixed Curtis (2007)
22
EPDS (health visitor 5 minutes) £7.57 Fixed Estimated from above inputs
BDI (health visitor 5 minutes + license fee) £8.59 Fixed Estimated from above inputs
SCID (health visitor 30 minutes) £45.50 Fixed Estimated from above inputs
Structured psychological therapy £446.67 Fixed Estimated from above inputs
Supportive care £414.00 Fixed Estimated from above inputs
EPDS=Edinburgh postnatal depression scale; BDI=Beck depression inventory; SCID=structured clinical interview for DSM-IV.
*Where applicable.
†At 1 April 2008.
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turedclinicalinterviewasaconfirmatorytestprovedto
be cost saving compared with the equivalent strategy
without the interview, although no strategy subse-
quently proved to be cost effective based on a thresh-
old of £20-30000 per QALY. Use of the Edinburgh
postnatal depression scale with a cut point of 13 with
confirmatorystructuredclinicalinterviewhadthelow-
est reported incremental cost effectiveness ratio of
£33776 per QALY compared with routine care.
When we considered the Whooley questions as an
alternativeidentificationmethodtheyprovednottobe
cost effective, with an incremental cost effectiveness
ratio of £46538 per QALY versus the strategy of
using the Edinburgh postnatal depression scale with a
cut point of 16 (itself not cost effective compared with
routine care only).
DISCUSSION
The use of formal identification methods for detecting
postnatal depression does not to represent value for
money for the NHS. Postnatal depression is an impor-
tant clinical, economic, and social problem which is
under-recognised and for which effective treatments
are available. Decisions to screen, however, have
attracted considerable controversy, and such policy
decisionsshouldbeinformedbysystematicconsidera-
tion of the clinical and economic evidence. In the
absence of prospective economic evidence collected
within randomised trials, decision models remain the
mostusefulmethodtoinformpracticeandpolicydeci-
sions and to identify areasof uncertainty and priorities
for further research. We used decision modelling to
address this problem and built on a recent and
comprehensive diagnostic meta-analysis of the perfor-
mance of screening instruments.
Our conclusions regarding the lack of cost effective-
nessareprimarilydrivenbythecostsofmanagingfalse
positives—that is, women with a misdiagnosis of
depressionataoneoffscreenwhodonotsubsequently
turnouttohavepostnataldepression.Whenthiscostis
relativelyhigh,thespecificityofaformalidentification
methodisanimportantcontributortoitscosteffective-
ness; as this cost falls, specificity becomes less impor-
tant relative to sensitivity. In the absence of reliable
data surrounding this cost, we used a conservative
approachinourbasecaseanalysis:comparedwithrou-
tine care the most cost effective formal identification
method (Edinburgh postnatal depression scale with a
cut point of 16) had an incremental cost effectiveness
ratio of £41103 per QALY. This ratio is well above a
conventionalthresholdofwillingnesstopayof£20000
-30000 per QALY. Furthermore, even when we
adopted a particularly optimistic estimate of this cost
(that of a single appointment with a general practi-
tioner) in a sensitivity analysis, compared with routine
care the most cost effective formal identification
method (Edinburgh postnatal depression scale with a
cut point of 10) had an incremental cost effectiveness
ratio of £29186 per QALY, falling only slightly under
the upper limit of the £20000-30000 per QALY cost
effectiveness threshold. As such, our main finding
seems to be robust to plausible estimates of the cost of
managing false positives. Nevertheless, a definitive
answer as to the cost effectiveness of formal identifica-
tion methods requires further evidence around this
particular cost.
A secondary finding is that adopting the structured
clinical interview as a confirmatory test for those posi-
tively identified by a formal identification method
provedtobecostsavingcomparedwiththeequivalent
strategy without such an interview; however, no such
strategy subsequently proved to be cost effective com-
pared with routine care only. This suggests that future
research into the cost associated with managing false
positives should also consider alternative approaches
to the management of those positively identified by a
formal identification method.
Strengths and limitations
We evaluated the relative performance of each identi-
ficationmethodusingbivariatemeta-analysis,withthe
data used to inform the meta-analysis derived from
several systematic searches of the literature. We used
probabilistic techniques to propagate parameter
uncertainty throughout the model. The model is com-
patible with the most recent best practice guidelines
from NICE for the methods of technology
appraisal.
25
The analysis was conducted from the perspective of
the NHS and personal social services and the model
focused on the costs and health outcomes associated
solely with the mother; no account was taken of the
potential impact that successful identification and sub-
sequent management might have had on other family
Table 3 |Results of base case analysis of screening for postnatal depression in primary care
Mean QALYs Mean costs ICER†
Probability cost effective*
£20 000 £30 000
Routine care only 0.8455 £49.29 NA 87.65 58.69
EPDS cut point:
16 0.8461 £73.49 £41 103 2.21 6.14
15 0.8462 £80.95 ED 0.70 1.82
14 0.8465 £94.21 £49 928 1.58 4.39
13 0.8467 £110.47 D 0.52 2.53
12 0.8468 £109.95 £56 697 1.77 6.11
BDI cut point:
10 0.8468 £121.51 D 1.15 5.07
EPDS cut point:
11 0.8468 £118.82 £113 411 1.86 5.87
10 0.8470 £140.44 £120 968 1.72 5.64
90 . 8 4 7 1 £156.95 £245 210 0.65 2.60
70 . 8 4 7 2 £215.07 D 0.01 0.04
80 . 8 4 7 2 £187.32 £272 463 0.18 1.10
ICER=incremental cost effectiveness ratio; NA=not applicable; EPDS=Edinburgh postnatal depression scale;
BDI=Beck depression inventory.
*Probability (in percentage) that strategy is more cost effective than all others given particular maximum
willingness to pay for additional QALY.
†D=dominated strategy (one or more alternative strategies are cheaper and more effective); ED=extended
dominance (one or more alternative strategies are more expensive but have lower ICER).
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societal perspective, were not considered because of
the lack of reliable evidence on the wider impact of
case identification or treatment strategies.
There were limited published data available for esti-
mating particular parameters in the model, including
theprobabilitythatpostnataldepressionwasidentified
viaroutinecareatsixweeks,theriskofrelapse,andthe
utility weights. As a result, we derived the estimates
used in the model from studies of general depressed
populations (that is, not postnatal women), which
represents a serious limitation of the model, particu-
larly with respect to the utility estimates adopted.
Further research specifically into the health related
quality of life of women with postnatal depression
would be valuable for future studies. The Edinburgh
postnatal depression scale was the only identification
strategy for which there were sufficient data at more
than one cut point to be able to combine results and
produce pooled summary estimates of sensitivity and
specificity; as such, the performance of other identifi-
cation strategies could not be assessed at multiple cut
points.Inaddition,therewereinsufficientdatatocarry
out subgroup analyses on different populations, such
aswomenofdifferentagesandwomenwithorwithout
complications after birth.
AfurtherissueisthedegreetowhichtheQALYisan
appropriate measure of health outcome. While the
QALY is used throughout the literature on evaluation
ofhealtheconomics,itmightbeaninsensitivemeasure
ofoutcomesinmentalhealthcare.
26Intheabsenceofa
suitablealternative,weusedtheQALYtoensurecom-
parability between the interventions considered here
and those outside mental health; the potential insensi-
tivity ofthe QALY in thiscontext,however,should be
considered in the interpretation of the results.
Finally,thereweremoderatetohighlevelsofhetero-
geneity between studies across all cut points of the
instruments considered. Consequently, we used ran-
domeffectsmeta-analysistoincorporatetheadditional
uncertainty caused by that heterogeneity in the test
performance results for each instrument. It has
recently been argued that conventional random effect
approaches might underestimate uncertainty by not
considering the whole distribution of effects and that
this additional uncertainty can be reflected by using a
predictioninterval.
27Inthecontextofdecisionmodels
analystscoulduseeitherthepredictivedistributionofa
future treatment effect or they should assume that
future implementation will result in a distribution of
treatment effects.
28 The importance of this issue
depends on the sources of heterogeneity in the evi-
dence and their relation to a future implementation,
both of which remain uncertain here given the limited
existing evidence base for several of the instruments.
Importantly from a policy perspective, the decision
modelpresentedhereislinearwithrespecttothepara-
meter inputs and the outputs used to establish the
incremental cost effectiveness ratios and hence our
conclusions would not be altered by using the predic-
tive distribution.
Policy issues
TheresultssuggestthatapplicationoftherecentNICE
guidance (which recommends the use of the Whooley
questions with an additional help question, see box 1)
and widespread current practice (which focuses on the
routine or ad hoc administration of the Edinburgh
postnatal depression scale) do not result in value for
money for the NHS. Formal methods of screening or
case identification do not seem to satisfy the National
Screening Committee’s criteria for the adoption of a
Table 4 |Results of sensitivity analyses of screening for postnatal depression in primary care results
Mean QALYs Mean costs ICER
Probability cost effective*
£20 000 £30 000
Scenario 1: Managing patients wrongly identified as depressed costs £ £25.50
Routine care only 0.8452 £50.33 NA 74.66 43.59
EPDS cut point:
10 0.8468 £95.26 £29 186 5.02 9.34
80 . 8 4 6 9 £100.74 £35 390 5.78 14.95
Scenario 2: SCID is adopted as confirmatory test
Routine care only 0.8450 £50.11 NA 83.62 52.61
EPDS cut point:
13 0.8462 £91.30 £33 776 1.14 3.16
10 0.8465 £102.49 £37 391 2.96 8.29
80 . 8 4 6 6 £110.00 £50 408 2.26 8.58
Scenario 3: Whooley questions is a feasible strategy
Routine care only 0.8455 £49.34 NA 88.52 59.78
EPDS cut point:
16 0.8461 £73.54 £41 175 2.08 5.15
Whooley questions 0.8473 £130.16 £46 538 0.27 3.43
ICER=incremental cost effectiveness ratio; EPDS=Edinburgh postnatal depression scale; NA=not applicable; SCID=structured clinical interview for DSM-
IV.
*Probability (in percentage) that strategy is more cost effective than all others given particular maximum willingness to pay for additional QALY for
non-dominated or extendedly dominated strategies only.
RESEARCH
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theiradoptiondoesnotrepresenta“favourableratioof
costs to benefits” according to conventional NHS cost
effectiveness thresholds.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Though cost effective treatments for postnatal depression are available, fewer than half of
cases of postnatal depression are detected by primary healthcare professionals in routine
clinical practice
Screening and case identification strategies have been advocated but have attracted
substantial controversy
Recent NICE guidance recommended the use of brief case finding questions (the Whooley
questions) to identify possible postnatal depression
WHAT THIS STUDY ADDS
Routine screening for postnatal depression does not seem to represent value for money for
the NHS, even with the use of a confirmatory test for those identified as depressed and with
adjustment for the costs of managing those misdiagnosed
Routine screening for postnatal depression does not satisfy the National Screening
Committee’s criteria for the adoption of a screening strategy as part of national health policy
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